PUBLISHER: TechSci Research | PRODUCT CODE: 1953516
PUBLISHER: TechSci Research | PRODUCT CODE: 1953516
Bloodstream Infection Testing Market - Global Industry Size, Share, Trends, Opportunity, & Forecast Segmented By Product, By Sample Type, By Technology, By End User, By Region & Competition, 2021-2031F
We offer 8 hour analyst time for an additional research. Please contact us for the details.
The Global Bloodstream Infection Testing Market is projected to expand from USD 850.50 Million in 2025 to USD 1140.41 Million by 2031, achieving a compound annual growth rate of 5.01%. This sector encompasses diagnostic instruments, consumables, and software utilized for the detection and identification of pathogens, such as bacteria and fungi, in blood samples. Growth is largely propelled by the rising incidence of sepsis and the critical necessity of managing antimicrobial resistance through accurate etiological diagnoses. Emphasizing this urgent need, the European Centre for Disease Prevention and Control reported in 2024 that the estimated total incidence of third-generation cephalosporin-resistant Escherichia coli bloodstream infections in the EU was 11.03 per 100,000 population, demonstrating the essential role of precise testing in directing therapeutic actions and enhancing patient recovery.
| Market Overview | |
|---|---|
| Forecast Period | 2027-2031 |
| Market Size 2025 | USD 850.50 Million |
| Market Size 2031 | USD 1140.41 Million |
| CAGR 2026-2031 | 5.01% |
| Fastest Growing Segment | Reagents and Consumables |
| Largest Market | North America |
However, the market faces significant hurdles due to the high costs and technical complexities linked to automated molecular diagnostic systems. Numerous healthcare facilities, especially within developing nations, contend with budgetary limitations that preclude the acquisition of these rapid testing solutions, necessitating a continued reliance on slower, traditional culture-based methods. These financial barriers impede timely treatment decisions and restrict the global reach of advanced diagnostic technologies, thereby limiting their availability in regions where they are frequently most essential.
Market Driver
The escalating challenge of antimicrobial resistance serves as a primary driver for the Global Bloodstream Infection Testing Market. As pathogens develop defenses against standard treatments, healthcare providers are increasingly seeking diagnostic tools capable of both identifying causative agents and determining antibiotic susceptibility profiles. This rise in resistant strains mandates the use of advanced testing platforms to facilitate precise therapeutic interventions and prevent fatalities. For instance, the UK Health Security Agency's November 2024 'English surveillance of antibiotic prescribing and utilisation report' highlighted that bacteraemia cases attributed to antibiotic resistance in England rose by 9.3% year-over-year, totaling 20,484 cases in 2024, underscoring the demand for diagnostics that manage resistant infections effectively.
Concurrently, breakthroughs in rapid molecular diagnostic technologies are transforming the speed and precision of pathogen detection. While traditional culture methods can take days to produce results-a potentially fatal delay in sepsis management-modern platforms offer actionable data within hours to optimize clinical workflows. A study published in the 'Journal of Clinical Microbiology' in March 2024 involving T2 Biosystems demonstrated that the T2Resistance Panel achieved 94.7% sensitivity and provided results in only 4.4 hours, compared to more than 58 hours for standard blood cultures. This functional advantage is attracting significant investment; according to Respiratory Therapy, diagnostic firm Cytovale secured $100 million in Series D funding in 2024 to accelerate the deployment of its rapid sepsis testing technology across hospital systems.
Market Challenge
The substantial expense and technical intricacy associated with automated molecular diagnostic platforms present a major obstacle to the expansion of the Global Bloodstream Infection Testing Market. High acquisition prices combined with the need for specialized operational skills make these systems unattainable for many healthcare facilities, particularly in areas facing strict financial constraints. These economic and operational barriers compel laboratories to rely on slower, traditional culture methods, which delays critical treatment decisions and hinders the widespread adoption of modern testing technologies.
This financial strain is further highlighted by the minimal budget allocation for diagnostic solutions, which restricts the purchasing capacity of medical institutions. According to MedTech Europe, expenditure on in vitro diagnostics accounted for merely 0.6% of total healthcare spending in Europe in 2024. Such restricted investment underscores the challenges facilities face in funding high-cost automated platforms. Consequently, market growth is directly impeded as the advanced capabilities of these instruments remain inaccessible to a significant portion of the global healthcare sector due to enduring funding limitations.
Market Trends
The integration of Artificial Intelligence and Machine Learning algorithms is fundamentally transforming clinical workflows by shifting focus from simple pathogen detection to predictive risk stratification. Unlike conventional diagnostics that identify organisms after an infection is established, AI models analyze host-immune responses and vital sign fluctuations to predict sepsis onset hours in advance, allowing clinicians to intervene before irreversible organ damage occurs. Validating this innovation, Prenosis announced in an April 2024 press release titled 'Prenosis Announces FDA De Novo Marketing Authorization of the Sepsis ImmunoScore' that it received the first-ever marketing authorization for an AI tool assessing 22 distinct parameters to evaluate patient sepsis risk.
Strategic industry consolidations and collaborative partnerships are further driving market evolution as major diagnostic players aim to provide comprehensive, end-to-end sepsis management solutions. Leading companies are acquiring niche software and technology firms to bridge the gap between diagnostic hardware and antimicrobial stewardship, converting standalone instruments into integrated data ecosystems that enhance hospital-wide decision-making. Illustrating this approach, bioMerieux announced in a January 2024 press release titled 'bioMerieux acquires LUMED to reinforce its software portfolio' that it completed an investment of nearly 9 million euros to acquire the remaining capital of the software developer, thereby fully integrating its clinical decision support systems into their global offering.
Key Market Players
- bioMerieux SA
- Becton, Dickinson and Company
- Cepheid
- Seegene Inc
- T2 Biosystems, Inc
- F. Hoffmann-La Roche Ltd
- Siemens Healthcare Private Limited
- Luminex Corporation
- Bruker Corporation
- Accelerate Diagnostics, Inc
Report Scope
In this report, the Global Bloodstream Infection Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Bloodstream Infection Testing Market, By Product
- Reagents & Consumables
- Instruments
Bloodstream Infection Testing Market, By Sample Type
- Whole Blood
- Blood Culture
Bloodstream Infection Testing Market, By Technology
- PCR
- Mass Spectroscopy
- In Situ Hybridization
- Others
Bloodstream Infection Testing Market, By End User
- Hospitals & Diagnostic Centers
- Custom Laboratory Service Providers
- Academic & Research Institutes
- Others
Bloodstream Infection Testing Market, By Region
- North America
- United States
- Canada
- Mexico
- Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Bloodstream Infection Testing Market.
Available Customizations:
Global Bloodstream Infection Testing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
- 1.1. Market Definition
- 1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations
2. Research Methodology
- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations
3. Executive Summary
- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Bloodstream Infection Testing Market Outlook
- 5.1. Market Size & Forecast
- 5.1.1. By Value
- 5.2. Market Share & Forecast
- 5.2.1. By Product (Reagents & Consumables, Instruments)
- 5.2.2. By Sample Type (Whole Blood, Blood Culture)
- 5.2.3. By Technology (PCR, Mass Spectroscopy, In Situ Hybridization, Others)
- 5.2.4. By End User (Hospitals & Diagnostic Centers, Custom Laboratory Service Providers, Academic & Research Institutes, Others)
- 5.2.5. By Region
- 5.2.6. By Company (2025)
- 5.3. Market Map
6. North America Bloodstream Infection Testing Market Outlook
- 6.1. Market Size & Forecast
- 6.1.1. By Value
- 6.2. Market Share & Forecast
- 6.2.1. By Product
- 6.2.2. By Sample Type
- 6.2.3. By Technology
- 6.2.4. By End User
- 6.2.5. By Country
- 6.3. North America: Country Analysis
- 6.3.1. United States Bloodstream Infection Testing Market Outlook
- 6.3.1.1. Market Size & Forecast
- 6.3.1.1.1. By Value
- 6.3.1.2. Market Share & Forecast
- 6.3.1.2.1. By Product
- 6.3.1.2.2. By Sample Type
- 6.3.1.2.3. By Technology
- 6.3.1.2.4. By End User
- 6.3.1.1. Market Size & Forecast
- 6.3.2. Canada Bloodstream Infection Testing Market Outlook
- 6.3.2.1. Market Size & Forecast
- 6.3.2.1.1. By Value
- 6.3.2.2. Market Share & Forecast
- 6.3.2.2.1. By Product
- 6.3.2.2.2. By Sample Type
- 6.3.2.2.3. By Technology
- 6.3.2.2.4. By End User
- 6.3.2.1. Market Size & Forecast
- 6.3.3. Mexico Bloodstream Infection Testing Market Outlook
- 6.3.3.1. Market Size & Forecast
- 6.3.3.1.1. By Value
- 6.3.3.2. Market Share & Forecast
- 6.3.3.2.1. By Product
- 6.3.3.2.2. By Sample Type
- 6.3.3.2.3. By Technology
- 6.3.3.2.4. By End User
- 6.3.3.1. Market Size & Forecast
- 6.3.1. United States Bloodstream Infection Testing Market Outlook
7. Europe Bloodstream Infection Testing Market Outlook
- 7.1. Market Size & Forecast
- 7.1.1. By Value
- 7.2. Market Share & Forecast
- 7.2.1. By Product
- 7.2.2. By Sample Type
- 7.2.3. By Technology
- 7.2.4. By End User
- 7.2.5. By Country
- 7.3. Europe: Country Analysis
- 7.3.1. Germany Bloodstream Infection Testing Market Outlook
- 7.3.1.1. Market Size & Forecast
- 7.3.1.1.1. By Value
- 7.3.1.2. Market Share & Forecast
- 7.3.1.2.1. By Product
- 7.3.1.2.2. By Sample Type
- 7.3.1.2.3. By Technology
- 7.3.1.2.4. By End User
- 7.3.1.1. Market Size & Forecast
- 7.3.2. France Bloodstream Infection Testing Market Outlook
- 7.3.2.1. Market Size & Forecast
- 7.3.2.1.1. By Value
- 7.3.2.2. Market Share & Forecast
- 7.3.2.2.1. By Product
- 7.3.2.2.2. By Sample Type
- 7.3.2.2.3. By Technology
- 7.3.2.2.4. By End User
- 7.3.2.1. Market Size & Forecast
- 7.3.3. United Kingdom Bloodstream Infection Testing Market Outlook
- 7.3.3.1. Market Size & Forecast
- 7.3.3.1.1. By Value
- 7.3.3.2. Market Share & Forecast
- 7.3.3.2.1. By Product
- 7.3.3.2.2. By Sample Type
- 7.3.3.2.3. By Technology
- 7.3.3.2.4. By End User
- 7.3.3.1. Market Size & Forecast
- 7.3.4. Italy Bloodstream Infection Testing Market Outlook
- 7.3.4.1. Market Size & Forecast
- 7.3.4.1.1. By Value
- 7.3.4.2. Market Share & Forecast
- 7.3.4.2.1. By Product
- 7.3.4.2.2. By Sample Type
- 7.3.4.2.3. By Technology
- 7.3.4.2.4. By End User
- 7.3.4.1. Market Size & Forecast
- 7.3.5. Spain Bloodstream Infection Testing Market Outlook
- 7.3.5.1. Market Size & Forecast
- 7.3.5.1.1. By Value
- 7.3.5.2. Market Share & Forecast
- 7.3.5.2.1. By Product
- 7.3.5.2.2. By Sample Type
- 7.3.5.2.3. By Technology
- 7.3.5.2.4. By End User
- 7.3.5.1. Market Size & Forecast
- 7.3.1. Germany Bloodstream Infection Testing Market Outlook
8. Asia Pacific Bloodstream Infection Testing Market Outlook
- 8.1. Market Size & Forecast
- 8.1.1. By Value
- 8.2. Market Share & Forecast
- 8.2.1. By Product
- 8.2.2. By Sample Type
- 8.2.3. By Technology
- 8.2.4. By End User
- 8.2.5. By Country
- 8.3. Asia Pacific: Country Analysis
- 8.3.1. China Bloodstream Infection Testing Market Outlook
- 8.3.1.1. Market Size & Forecast
- 8.3.1.1.1. By Value
- 8.3.1.2. Market Share & Forecast
- 8.3.1.2.1. By Product
- 8.3.1.2.2. By Sample Type
- 8.3.1.2.3. By Technology
- 8.3.1.2.4. By End User
- 8.3.1.1. Market Size & Forecast
- 8.3.2. India Bloodstream Infection Testing Market Outlook
- 8.3.2.1. Market Size & Forecast
- 8.3.2.1.1. By Value
- 8.3.2.2. Market Share & Forecast
- 8.3.2.2.1. By Product
- 8.3.2.2.2. By Sample Type
- 8.3.2.2.3. By Technology
- 8.3.2.2.4. By End User
- 8.3.2.1. Market Size & Forecast
- 8.3.3. Japan Bloodstream Infection Testing Market Outlook
- 8.3.3.1. Market Size & Forecast
- 8.3.3.1.1. By Value
- 8.3.3.2. Market Share & Forecast
- 8.3.3.2.1. By Product
- 8.3.3.2.2. By Sample Type
- 8.3.3.2.3. By Technology
- 8.3.3.2.4. By End User
- 8.3.3.1. Market Size & Forecast
- 8.3.4. South Korea Bloodstream Infection Testing Market Outlook
- 8.3.4.1. Market Size & Forecast
- 8.3.4.1.1. By Value
- 8.3.4.2. Market Share & Forecast
- 8.3.4.2.1. By Product
- 8.3.4.2.2. By Sample Type
- 8.3.4.2.3. By Technology
- 8.3.4.2.4. By End User
- 8.3.4.1. Market Size & Forecast
- 8.3.5. Australia Bloodstream Infection Testing Market Outlook
- 8.3.5.1. Market Size & Forecast
- 8.3.5.1.1. By Value
- 8.3.5.2. Market Share & Forecast
- 8.3.5.2.1. By Product
- 8.3.5.2.2. By Sample Type
- 8.3.5.2.3. By Technology
- 8.3.5.2.4. By End User
- 8.3.5.1. Market Size & Forecast
- 8.3.1. China Bloodstream Infection Testing Market Outlook
9. Middle East & Africa Bloodstream Infection Testing Market Outlook
- 9.1. Market Size & Forecast
- 9.1.1. By Value
- 9.2. Market Share & Forecast
- 9.2.1. By Product
- 9.2.2. By Sample Type
- 9.2.3. By Technology
- 9.2.4. By End User
- 9.2.5. By Country
- 9.3. Middle East & Africa: Country Analysis
- 9.3.1. Saudi Arabia Bloodstream Infection Testing Market Outlook
- 9.3.1.1. Market Size & Forecast
- 9.3.1.1.1. By Value
- 9.3.1.2. Market Share & Forecast
- 9.3.1.2.1. By Product
- 9.3.1.2.2. By Sample Type
- 9.3.1.2.3. By Technology
- 9.3.1.2.4. By End User
- 9.3.1.1. Market Size & Forecast
- 9.3.2. UAE Bloodstream Infection Testing Market Outlook
- 9.3.2.1. Market Size & Forecast
- 9.3.2.1.1. By Value
- 9.3.2.2. Market Share & Forecast
- 9.3.2.2.1. By Product
- 9.3.2.2.2. By Sample Type
- 9.3.2.2.3. By Technology
- 9.3.2.2.4. By End User
- 9.3.2.1. Market Size & Forecast
- 9.3.3. South Africa Bloodstream Infection Testing Market Outlook
- 9.3.3.1. Market Size & Forecast
- 9.3.3.1.1. By Value
- 9.3.3.2. Market Share & Forecast
- 9.3.3.2.1. By Product
- 9.3.3.2.2. By Sample Type
- 9.3.3.2.3. By Technology
- 9.3.3.2.4. By End User
- 9.3.3.1. Market Size & Forecast
- 9.3.1. Saudi Arabia Bloodstream Infection Testing Market Outlook
10. South America Bloodstream Infection Testing Market Outlook
- 10.1. Market Size & Forecast
- 10.1.1. By Value
- 10.2. Market Share & Forecast
- 10.2.1. By Product
- 10.2.2. By Sample Type
- 10.2.3. By Technology
- 10.2.4. By End User
- 10.2.5. By Country
- 10.3. South America: Country Analysis
- 10.3.1. Brazil Bloodstream Infection Testing Market Outlook
- 10.3.1.1. Market Size & Forecast
- 10.3.1.1.1. By Value
- 10.3.1.2. Market Share & Forecast
- 10.3.1.2.1. By Product
- 10.3.1.2.2. By Sample Type
- 10.3.1.2.3. By Technology
- 10.3.1.2.4. By End User
- 10.3.1.1. Market Size & Forecast
- 10.3.2. Colombia Bloodstream Infection Testing Market Outlook
- 10.3.2.1. Market Size & Forecast
- 10.3.2.1.1. By Value
- 10.3.2.2. Market Share & Forecast
- 10.3.2.2.1. By Product
- 10.3.2.2.2. By Sample Type
- 10.3.2.2.3. By Technology
- 10.3.2.2.4. By End User
- 10.3.2.1. Market Size & Forecast
- 10.3.3. Argentina Bloodstream Infection Testing Market Outlook
- 10.3.3.1. Market Size & Forecast
- 10.3.3.1.1. By Value
- 10.3.3.2. Market Share & Forecast
- 10.3.3.2.1. By Product
- 10.3.3.2.2. By Sample Type
- 10.3.3.2.3. By Technology
- 10.3.3.2.4. By End User
- 10.3.3.1. Market Size & Forecast
- 10.3.1. Brazil Bloodstream Infection Testing Market Outlook
11. Market Dynamics
- 11.1. Drivers
- 11.2. Challenges
12. Market Trends & Developments
- 12.1. Merger & Acquisition (If Any)
- 12.2. Product Launches (If Any)
- 12.3. Recent Developments
13. Global Bloodstream Infection Testing Market: SWOT Analysis
14. Porter's Five Forces Analysis
- 14.1. Competition in the Industry
- 14.2. Potential of New Entrants
- 14.3. Power of Suppliers
- 14.4. Power of Customers
- 14.5. Threat of Substitute Products
15. Competitive Landscape
- 15.1. bioMerieux SA
- 15.1.1. Business Overview
- 15.1.2. Products & Services
- 15.1.3. Recent Developments
- 15.1.4. Key Personnel
- 15.1.5. SWOT Analysis
- 15.2. Becton, Dickinson and Company
- 15.3. Cepheid
- 15.4. Seegene Inc
- 15.5. T2 Biosystems, Inc
- 15.6. F. Hoffmann-La Roche Ltd
- 15.7. Siemens Healthcare Private Limited
- 15.8. Luminex Corporation
- 15.9. Bruker Corporation
- 15.10. Accelerate Diagnostics, Inc
16. Strategic Recommendations
17. About Us & Disclaimer
